title: A synthetic form of frizzled 8-associated antiproliferative factor enhances p53 stability through USP2a and MDM2.
abstract: Frizzled 8-associated Antiproliferative Factor (APF) is a sialoglycopeptide urinary biomarker of interstitial cystitis/painful bladder syndrome (IC/PBS), a chronic condition of unknown etiology with variable symptoms that generally include pelvic and/or perineal pain, urinary frequency, and urgency. We previously reported that native human APF suppresses the proliferation of normal bladder epithelial cells through a mechanism that involves increased levels of p53. The goal of this study was to delineate the regulatory mechanism whereby p53 expression is regulated by APF. Two APF-responsive cell lines (T24 bladder carcinoma cells and the immortalized human bladder epithelial cell line, TRT-HU1) were treated with asialo-APF (as-APF), a chemically synthesized form of APF. Biochemical analysis revealed that as-APF increased p53 levels in two ways: by decreasing ubiquitin specific protease 2a (USP2a) expression leading to enhanced ubiquitination of murine double minute 2 E3 ubiquitin ligase (MDM2), and by suppressing association of p53 with MDM2, thus impairing p53 ubiquitination. Biological responses to as-APF were suppressed by increased expression of wild type, but not mutant USP2a, which enhanced cell growth via upregulation of a cell cycle mediator, cyclin D1, at both transcription and protein levels. Consistent with this, gene silencing of USP2a with siRNA arrested cell proliferation. Our findings suggest that APF upregulates cellular p53 levels via functional attenuation of the USP2a-MDM2 pathway, resulting in p53 accumulation and growth arrest. These data also imply that targeting USP2a, MDM2, p53 and/or complex formation by these molecules may be relevant in the development of novel therapeutic approaches to IC/PBS.
authors.affiliation: Division of Cancer Biology and Therapeutics, Departments of Surgery and Biomedical Sciences, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA. Jayoung.Kim@cshs.org
authors.forename: Jayoung
authors.initials: J
authors.lastname: Kim
authors.forename: Susan K
authors.initials: SK
authors.lastname: Keay
authors.forename: Sungyong
authors.initials: S
authors.lastname: You
authors.forename: Massimo
authors.initials: M
authors.lastname: Loda
authors.forename: Michael R
authors.initials: MR
authors.lastname: Freeman
mesh_terms: D002460:Cell Line; D049109:Cell Proliferation / Q000187:drug effects; D010450:Endopeptidases / Q000235:genetics / Q000378:metabolism*; D004847:Epithelial Cells / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*; D006023:Glycoproteins / Q000494:pharmacology*; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins; D051736:Proto-Oncogene Proteins c-mdm2 / Q000235:genetics / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics / Q000378:metabolism*; D043222:Ubiquitin Thiolesterase; D054875:Ubiquitination; D001743:Urinary Bladder / Q000166:cytology / Q000187:drug effects / Q000378:metabolism*
chemical_list: D006023:Glycoproteins; D036341:Intercellular Signaling Peptides and Proteins; D016159:Tumor Suppressor Protein p53; C490708:antiproliferative factor APF, human; C497206:MDM2 protein, human; D051736:Proto-Oncogene Proteins c-mdm2; D010450:Endopeptidases; C108665:USP2 protein, human; D043222:Ubiquitin Thiolesterase